Abstract 1164P
Background
The standard approach for managing locally advanced rectal cancer includes preoperative neoadjuvant chemoradiotherapy followed by curative surgery, a regimen acknowledged for substantially enhancing local control rates. Nevertheless, the benefits of perioperative radiotherapy in treating rectal neuroendocrine carcinoma merit further investigation. This study explores the impact of preoperative neoadjuvant radiotherapy on the feasibility of sphincter-preserving surgery and on the overall survival rates in patients with locally advanced rectal neuroendocrine carcinoma.
Methods
Data from patients diagnosed with locally advanced (T3/T4 or N+) neuroendocrine carcinoma who underwent curative surgery from 2004 to 2019 were collected using the SEER database. We assessed clinical characteristics, treatment information, and overall survival rates. Statistical comparisons of categorical variables were performed using the Chi-square test or Fisher's exact test. Survival outcomes were analyzed using the Kaplan-Meier method.
Results
Of the 44 patients identified, 14 underwent preoperative neoadjuvant radiotherapy. Patients with a T-stage above T3 (42.9% vs. 12.5%, P = 0.049) and those without lymph node metastasis (87.5% vs. 19.4%, P < 0.001) were more likely to receive perioperative radiotherapy. The probability of performing sphincter-preserving surgery was notably lower in patients treated with neoadjuvant radiotherapy (57.1% vs. 93.3%, P = 0.008). Additionally, survival analysis indicated no significant relationship between neoadjuvant radiotherapy and overall survival (HR 1.298,95% CI:0.519-3. 244, P =0. 577).
Conclusions
Neoadjuvant radiotherapy prior to surgery did not improve the likelihood of performing sphincter-preserving procedures in patients with locally advanced rectal neuroendocrine carcinoma, nor did it significantly impact overall survival. Further research involving larger sample sizes is required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work, the author(s) used ChatGPT for editorial assistance in order to optimize content expression. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
W. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1427P - Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysis
Presenter: Nguyen-Kieu Viet-Nhi
Session: Poster session 17
1428P - Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study
Presenter: Hollie Clements
Session: Poster session 17
1429P - Differences in esophageal cancer incidence and survival by race/ethnicity: A SEER analysis
Presenter: Ashwin Kulshrestha
Session: Poster session 17
1430P - Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trial
Presenter: Francisco Cezar Moraes
Session: Poster session 17
1431P - Assessing pathological complete response to neoadjuvant chemotherapy combined with immunotherapy in esophageal squamous cell carcinoma: A deep learning approach with voxel-level radiomics
Presenter: Yongling Ji
Session: Poster session 17
1432P - Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a)
Presenter: Kun Yang
Session: Poster session 17